Clinicopathological significance of cell cycle regulatory factors and differentiation-related factors in pancreatic neoplasms

Pancreas

Volumn 39, Issue 3, 2010, Pages 345-352

  Kamio, Yukinori ^a   Maeda, Kunihiko ^a   Moriya, Toshiyuki ^a   Takasu, Naoki ^a   Takeshita, Akiko ^a   Hirai, Ichiro ^a   Kimura, Wataru ^a   Yamakawa, Mitsunori ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Cyclin A; Cyclin B1; EID 1; Intraductal papillary mucinous neoplasms of the pancreas; Ordinary ductal carcinoma of the pancreas

Indexed keywords

ACETYLATED HISTONE H3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN A; CYCLIN B1; E1A LIKE INHIBITOR OF DIFFERENTIATION 1; HISTONE H3; PROTEIN; PROTEIN P300; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL; CELL CYCLE REGULATION; CELL DIFFERENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS ADENOMA; INTRADUCTAL PAPILLARY MUCINOUS CARCINOMA; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; ORDINARY DUCTAL CARCINOMA; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS;

ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; AGED; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE PROTEINS; CREB-BINDING PROTEIN; CYCLIN A; CYCLIN B1; CYCLINS; FEMALE; HISTONES; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; REPRESSOR PROTEINS;

EID: 77950259400     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181bb9204     Document Type: Article

References (32)

1. Miyake S, Sellers WR, Safran M, et al. Cells degrade a novel inhibitor of differentiation with E1A-like properties upon existing the cell cycle. Mol Cell Biol. 2000;20:8889-8902.
2. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol. 1995;147: 545-560.
3. Hunter T, Pines J. Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell. 1994;79:573-582.
4. Sellers WR, Novitch BG, Miyake S, et al. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev. 1998;12:95-106.
5. Lipinski MM, Jacks T. The retinoblastoma gene family in differentiation and development. Oncogene. 1999;18:7873-7882.
6. Ji A, Dao D, Chen J, et al. EID-2, a novel member of the EID family of p300-binding proteins inhibits transactivation by MyoD. Gene. 2003; 318:35-43.
7. Warshaw AL, Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455-465.
8. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg. 2001;234:313-322.
9. Kimura W, Sasahira N, Yoshikawa T, et al. Duct-ectatic type of mucin producing tumor of the pancreasVnew concept of pancreatic neoplasia. Hepatogastroenterology. 1996;43:692-709.
10. Kimura W, Kuroda A, Makuuchi M. Problems in the diagnosis and treatment of a so-called mucin-producing tumor of the pancreas. Pancreas. 1998;16:363-369.
11. Moriya T, Kimura W, Semba S, et al. Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms. Int J Gastrointest Cancer. 2005;35: 111-119.
12. Sobin LH, Gospodarowics MK, Wittekind C. UICC International Union Against Cancer. UICC International Union Against Cancer. TNM classification of malignant tumours. 7th ed. Singapore: Wiley-Blackwell; 2010.
13. Girard F, Strausfeld U, Fernandez A, et al. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell. 1991;67: 1169-1179.
14. Moore NL, Narayanan R, Weigel NL. Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. Steroids. 2007; 72:202-209.
15. Pagano M, Pepperkok R, Verde F, et al. Cyclin A is required at two points in the human cell cycle. EMBO J. 1992;11:961-971.
16. Volm M, Koomägi R, Mattern J, et al. Cyclin A is associated with an unfavorable outcome in patients with non-small-cell lung carcinomas. Br J Cancer. 1997;75:1774-1778.
17. Chao Y, Shih YL, Chiu JH, et al. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res. 1998;58:985-990.
18. Handa K, Yamakawa M, Takeda H, et al. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer. 1999;84:225-233.
19. Nozoe T, Korenaga D, Kabashima A, et al. Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res. 2002; 8:817-822.
20. Suzuki T, Urano T, Miki Y, et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 2007;98: 644-651.
21. Krützfeldt M, Ellis M, Weekes DB, et al. Selective ablation of retinoblastoma protein function by the RET finger protein. Mol Cell. 2005;18:213-224.
22. Haumaitre C, Lenoir O, Scharfmann R. Directing cell differentiation with small-molecule histone deacetylase inhibitors: the example of promoting pancreatic endocrine cells. Cell Cycle. 2009;8(4):536-544.
23. Lennartsson A, Ekwall K. Histone modification patterns and epigenetic codes. Biochim Biophys Acta. 2009;1790:863-868.
24. Hoffmann AC, Mori R, Vallbohmer D, et al. High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF. J Gastrointest Surg. 2008;12:1674-1681.
25. Dittert DD, Kielisch C, Alldinger I, et al. Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis. Hum Pathol. 2008; 39:1002-1010.
26. Ishihama K, Yamakawa M, Semba S, et al. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol. 2007;60:1205-1210.
27. Sugiyama M, Suzuki Y, Abe N, et al. Management of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol. 2008;43:181-185.
28. Katabi N, Klimstra DS. Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach. J Clin Pathol. 2008;61:1303-1313.
29. Jinfeng M, KimuraW, Hirai I, et al. Expression of MUC5AC and MUC6 in invasive ductal carcinoma of the pancreas and relationship with prognosis. Int J Gastrointest Cancer. 2003;34:9-18.
30. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60: 2002-2006.
31. Moriya T, Kimura W, Sakurai F, et al. Minute invasive ductal carcinoma of the residual pancreas after distal pancreatectomy for intraductal papillary-mucinous tumor. Int J Gastrointest Cancer. 2002;31:191-197.
32. Mukawa K, Kawa S, Aoki Y, et al. Reduced expression of p53 and cyclin A in intraductal mucin-hypersecreting neoplasm of the pancreas compared with usual pancreatic ductal adenocarcinoma. Am J Gastroenterol. 1999;94:2263-2267.